EVFM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EVFM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Evofem Biosciences's Net Cash per Share for the quarter that ended in Dec. 2024 was $-0.84.
The historical rank and industry rank for Evofem Biosciences's Net Cash per Share or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Cash Ratio of Evofem Biosciences was 26.99. The lowest was 0.73. And the median was 1.19.
The historical data trend for Evofem Biosciences's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evofem Biosciences Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Net Cash per Share | Get a 7-Day Free Trial |
![]() |
![]() |
-1,389.05 | -1,544.31 | -95.63 | -3.85 | -0.84 |
Evofem Biosciences Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Net Cash per Share | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-3.85 | -1.52 | -0.88 | -0.90 | -0.84 |
For the Biotechnology subindustry, Evofem Biosciences's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Evofem Biosciences's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Evofem Biosciences's Net Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as
Net Cash per Share (A: Dec. 2024 ) | |||||||
= | (Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | - | Minority Interest) | / | Shares Outstanding (EOP) |
= | (0 | - | 95.046 | - | 0) | / | 113.356 |
= | -0.84 |
Evofem Biosciences's Net Cash per Share for the quarter that ended in Dec. 2024 is calculated as
Net Cash per Share (Q: Dec. 2024 ) | = | (Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | - | Minority Interest) | / | Shares Outstanding (EOP) |
= | (0 | - | 95.046 | - | 0) | / | 113.356 |
= | -0.84 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evofem Biosciences (OTCPK:EVFM) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Thank you for viewing the detailed overview of Evofem Biosciences's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Yan Zhang | officer: Chief Financial Officer | 6166 TIKI CT, SAN DIEGO CA 92130 |
Kim P. Kamdar | director, 10 percent owner | C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542 |
Jenny C. Yip | director | 12400 HIGH BLUFF DR., STE. 600, SAN DIEGO CA 92130 |
Atkinson Katherine Cocca | officer: Chief Commercial Officer | 12400 HIGH BLUFF., STE. 600, SAN DIEGO CA 92130 |
Saundra L Pelletier | director, officer: Chief Executive Officer | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
Alexander A Fitzpatrick | officer: General Counsel and Secretary | 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121 |
Justin J. File | officer: Chief Financial Officer | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
Anthony Stephen O'brien | director | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
Russell Barrans | officer: Chief Commercial Officer | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
Lisa Dale Rarick | director | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, STE 600, SAN DIEGO CA 92130 |
William Walmsley Hall | director | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DIRVE, SUITE 600, SAN DIEGO CA 92130 |
Invesco Ltd. | 10 percent owner | 1331 SPRING STREET NW, SUITE 2500, ATLANTA GA 30309 |
Link Fund Solutions Ltd | 10 percent owner | 65 GRESHAM STREET, LONDON X0 EC2V 7NQ |
Acacia Research Corp | 10 percent owner | 767 3RD AVENUE, 6TH FLOOR, NEW YORK NY 10017 |
Kelly Culwell | officer: Chief Medical Officer | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
From GuruFocus
By GuruFocus Research • 02-13-2024
By GuruFocus Research • 02-13-2024
By PRNewswire • 05-15-2024
By PRNewswire • 08-20-2024
By GuruFocus Research • 02-13-2024
By PRNewswire • 03-07-2024
By PRNewswire • 04-18-2024
By PRNewswire • 11-06-2024
By GuruFocus Research • 02-13-2024
By PRNewswire • 08-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.